WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016104678) MEDICAL COMPOSITION FOR PROMOTING FIBRINOLYSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/104678    International Application No.:    PCT/JP2015/086178
Publication Date: 30.06.2016 International Filing Date: 25.12.2015
IPC:
A61K 31/444 (2006.01), A61K 36/81 (2006.01), A61K 45/00 (2006.01), A61P 7/02 (2006.01), A61P 43/00 (2006.01)
Applicants: DAIICHI SANKYO COMPANY,LIMITED [JP/JP]; 3-5-1,Nihonbashi Honcho,Chuo-ku, Tokyo 1038426 (JP)
Inventors: FURUGORI, Taketoshi; (JP).
MORISHIMA, Yoshiyuki; (JP)
Agent: ISHIBASHI, Koki; (JP)
Priority Data:
2014-263765 26.12.2014 JP
Title (EN) MEDICAL COMPOSITION FOR PROMOTING FIBRINOLYSIS
(FR) COMPOSITION MÉDICALE DESTINÉE À PROMOUVOIR LA FIBRINOLYSE
(JA) 線溶を促進するための医薬組成物
Abstract: front page image
(EN)Provided is a novel medical composition capable of promoting fibrinolysis. The medical composition for promoting fibrinolysis contains edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of those. In addition to edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of those, the medical composition for promoting fibrinolysis further contains a TAFIa inhibitor.
(FR)La présente invention concerne une nouvelle composition médicale capable de promouvoir la fibrinolyse. La composition médicale destinée à promouvoir la fibrinolyse contient de l'edoxaban ou un de ses sels pharmaceutiquement acceptables, ou un de leurs hydrates. En plus de l'edoxaban ou d'un de ses sels pharmaceutiquement acceptables, ou d'un de leurs hydrates, la composition médicale destinée à promouvoir la fibrinolyse contient un inhibiteur de TAFIa.
(JA)線溶を促進できる新たな医薬組成物を提供すること。 エドキサバンまたはその薬学的に許容され得る塩あるいはそれらの水和物を含有する、線溶を促進するための医薬組成物。エドキサバンまたはその薬学的に許容され得る塩あるいはそれらの水和物TAFIa阻害剤をさらに含有する線溶を促進するための医薬組成物。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)